SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Malmberg M)
 

Search: WFRF:(Malmberg M) > (2010-2014) > Serum thymidine kin...

  • Bjohle, JKarolinska Institutet,Karolinska Institute, Sweden (author)

Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013-06-05
  • Springer Verlag (Germany),2013
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-95969
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-95969URI
  • https://doi.org/10.1007/s10549-013-2579-xDOI
  • https://lup.lub.lu.se/record/3979136URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:126909602URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-205379URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|Swedish Cancer Society||Stockholm Cancer Society||King Gustav V Jubilee Fund||Swedish Research Council||Stockholm City Council||Karolinska Institutet||Stockholm County Council Research Strategy Committee||BRECT||Swedish Breast Cancer Association||Marit and Hans Rausings Initiative Against Breast Cancer||Karolinska Institutet Research Funds||Biovica International AB||
  • The primary objective was to estimate serum thymidine kinase 1 (TK1) activity, reflecting total body cell proliferation rate including cancer cell proliferation, in women with loco regional inoperable or metastatic breast cancer participating in a prospective and randomized study. Secondary objectives were to analyze TK1 in relation to progression-free survival (PFS), overall survival (OS), therapy response and other tumour characteristics, including CA 15-3, widely used as a standard serum marker for disease progression. TK1 and CA 15-3 were analysed in 198 serum samples collected prospectively from women included in the randomized TEX trial between December 2002 and June 2007. TK1 activity was determined by the ELISA based DiviTum (TM) assay, and CA 15-3 analyses was generated with the electrochemiluminescence immunoassay Cobas Elecsys CA 15-3 II. High pre-treatment TK1 activity predicted shorter PFS (10 vs. 15 months p = 0.02) and OS (21 vs. 38 months, p andlt; 0.0001), respectively. After adjustment for age, metastatic site and study treatment TK1 showed a trend as predictor of PFS (p = 0.059) and was an independent prognostic factor for OS, (HR 1.81, 95 % confidence interval (CI) 1.26-2.61, p = 0.001). There was a trend of shortened OS for women with high CA 15-3 (p = 0.054) in univariate analysis, but not after adjustment for the above mentioned covariates. Both TK1 (p = 0.0011) and CA 15-3 (p = 0.0004) predicted response to treatment. There were statistically different distributions of TK1 and CA 15-3 in relation to the site of metastases. TK1 activity measured by DiviTum (TM) predicted therapy response, PFS and OS in loco regional inoperable or disseminated breast cancer. These results suggest that this factor is a useful serum marker. In the present material, a prognostic value of CA 15-3 could not be proven.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bergqvist, JKarolinska Institutet,Karolinska Institute, Sweden (author)
  • Gronowitz, J. SimonUppsala universitet,Klinisk virologi,Biov Int AB, Sweden(Swepub:uu)simongro (author)
  • Johansson, HKarolinska Institutet,Karolinska Institute, Sweden (author)
  • Carlsson, LSundsvall Gen Hospital, Sweden (author)
  • Einbeigi, ZSahlgrens University Hospital, Sweden (author)
  • Linderholm, BKarolinska Institutet,Sahlgrens University Hospital, Sweden (author)
  • Loman, NiklasLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University, Sweden(Swepub:lu)onk-nlo (author)
  • Malmberg, MHelsingborg Gen Hospital, Sweden,Lund University, Sweden,Kalmar Gen Hospital, Sweden (author)
  • Soderberg, MLund University, Sweden (author)
  • Sundquist, MKalmar Gen Hospital, Sweden (author)
  • Walz, ThomasÖstergötlands Läns Landsting,Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet,Onkologiska kliniken US,Karolinska Institute, Sweden(Swepub:liu)thowa08 (author)
  • Fernö, MårtenLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-mfe (author)
  • Bergh, JKarolinska Institutet,Karolinska Institute, Sweden (author)
  • Hatschek, TKarolinska Institutet,Karolinska Institute, Sweden (author)
  • Karolinska InstitutetKarolinska Institute, Sweden (creator_code:org_t)

Related titles

  • In:Breast Cancer Research and Treatment: Springer Verlag (Germany)139:3, s. 751-7580167-68061573-7217

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view